To examine relapse, survival and transplant-related complications in relationship to disease-and pre-treatment-related characteristics, we evaluated 132 children, who consecutively received an allogeneic HLA-identical SCT for acute leukaemia in our centre: ALL in first remission (n ¼ 24), ALL in second remission (n ¼ 53) and AML in first remission (n ¼ 55). The source of the stem cells was bone marrow in all but three cases. Most patients (89%) were pre-treated with cyclophosphamide and an age-related dose of TBI. Initially, GVHD prophylaxis consisted of long-course MTX only (n ¼ 24), later shortcourse MTX and CsA (n ¼ 102) was given. All patients were nursed in strictly protective isolation and received total gut decontamination to suppress their potentially pathogenic enteric microflora. The 5-year probability of overall survival was 63, 53 and 74% for ALL1, ALL2 and AML1, respectively (median follow-up: 10.6 years). The overall transplant-related mortality was 6%. The incidence of acute GVHD was 17%; 6% was grades II-IV. A higher total biologically effective TBI dose (BED) resulted in a decreased relapse frequency (P ¼ 0.034) and increased overall survival. AML patients with acute GVHD got no relapse (P ¼ 0.02); this was not the case in ALL patients. Fractionated TBI regimens with higher BED should be evaluated in prospective studies.
Introduction
The prognosis in terms of cure and survival of children with acute leukaemia has improved impressively over the last four decades, following protocolized chemotherapy regimens applied in large prospective studies. Currently, 80-90% of children diagnosed with ALL and AML achieve first CR (CR1), and up to 60 and 80% for AML and ALL, respectively, reach a sustained CR and long-term survival with chemotherapy alone. [1] [2] [3] [4] [5] In 'high risk' ALL, sustained first CR is obtained in only 30-60% of the patients according to different studies. 6, 7 Outcomes after relapse remain poor. Reported event-free survival rates are between 14 and 50% in ALL patients, depending on their risk profile and treatment modality, [8] [9] [10] [11] and 2-year overall survival (OS) rates are around 20% in retreated AML patients. 12 For high-risk leukaemia patients, an allogeneic SCT is still the preferable alternative treatment to reach cure. 13 The major cause of failure after haematopoietic SCT in childhood leukaemia is relapse of the disease, followed by transplant-related mortality (TRM) as a result of GVHD, drug toxicity and infections.
For patients undergoing allogeneic SCT for leukaemia, TBI was and still is, despite a number of adverse late effects, a major component of the conditioning regimen. A randomized study in adults with CML on the dose of TBI delivered before SCT confirmed that a higher total dose of TBI (15.75 vs 12 Gy) resulted in a lower probability of relapse.
14 This is, however, at the cost of greater TRM. A similar TBI dose-related effect on relapse was seen for adults with AML in first CR (CR1) 15, 16 and with ALL. 17 Another possibly important variable with respect to the occurrence of relapse is the so-called 'GVL effect'. This effect is thought to be mediated by alloreactive T cells and/ or NK cells from the donor. 18, 19 Retrospective evaluation of large numbers of patients clearly showed that GVHD, as equivalent for a reaction of donor T cells towards recipient's histocompatibility antigens, suppresses leukaemia recurrence after SCT. Donor lymphocyte infusions (DLI), however, seem to be much more effective in cytogenetic relapses of CML than in AML, and are barely effective in ALL. 20 Here, we summarize the results of 132 children with acute leukaemia who consecutively received transplants from HLA-identical sibling donors (matched sibling donor (MSD)). We retrospectively analyzed potentially relevant risk factors for the occurrence of relapse of the disease, development of GVHD, TRM and OS after SCT.
Patients and methods

Patients
From September 1980 to September 2002, a total number of 132 children received an allogeneic haematopoietic SCT with a MSD for the treatment of acute leukaemia in the paediatric SCT unit of the Leiden University Medical Centre, The Netherlands. The characteristics of these patients are given in Table 1 . Seventy-seven children suffered from ALL and 55 from AML. Patients with a secondary AML and patients in either partial first remission, second (for AML) or third remission were excluded from this analysis. All but nine patients were treated according to the treatment protocols of the Dutch Childhood Leukaemia Study Group (DCLSG); also the indication for MSD-SCT was according to the successive DCLSG protocols. The number of patients at increased risk for relapse according to recent criteria 3, 7, [21] [22] [23] [24] is given in Table 1 . The median age at the time of SCT was 8.5 years (range: 1.1-17.3). The median follow-up time after SCT was 10.6 years (range: 1.3-23.3), the cut-off point for the evaluation being 1 January 2004.
Graft characteristics and transplant procedures
All patients were transplanted with genotypically HLAidentical grafts, donated by siblings. Donor and transplant characteristics are summarized in Table 2 . Most patients, 118 out of 132, were conditioned using a TBI-cyclophosphamide (total dose: 120 mg/kg)-based therapy. Nine patients were conditioned with a busulphan (total dose: 20 mg/kg)-cyclophosphamide-based regimen: eight of them because of their young age (mean: 1.8 years; range: 1.1-2.6) and one because of a personalized conditioning regimen, due to earlier toxicity of treatment. In addition to the basic conditioning, 56 ALL patients also received VP-16 (total dose: 350 mg/m 2 ), and 28 AML patients also received ARA-C (total dose: 2000 mg/m 2 ) in their pre-treatment. This was a time-related change of the protocol, in accordance with the treatment protocols of the DCLSG. Individualized conditioning regimens were used in seven Figure 1 ). In general, children between 2 and 4 years received 1 Â 7 Gy, those between 4 and 10 years received 1 Â 7.5 Gy, and children older than 10 years received 1 Â 8 Gy, before 1990, and 2 Â 6 Gy (total dose: 12 Gy) on two consecutive days, after 1990.
Post-SCT immunosuppression and supportive care
Up to 1986, GVHD prophylaxis consisted of a long-course MTX only, later on a short-course MTX combined with CsA prophylaxis was used. 25 The long-course of MTX consisted of 15 mg/m 2 at day þ 1, and 10 mg/m 2 at days þ 3, þ 6, þ 11 and weekly thereafter until day þ 102. Short-course MTX was given at a dose of 10 mg/m 2 intravenously at days þ 1, þ 3, and þ 6 (and in some, þ 11), and was combined with CsA 2 mg/kg/day intravenously from day -1 until oral medication was tolerated at a dose of 6 mg/kg/day, using dose adjustment for upper levels (potential toxicity level X200 mg/l) according to the results of weekly blood sampling. This was continued for 180 days, tapered thereafter and finally stopped. All patients were nursed in strict protective isolation using positive-pressure laminar air flow cubicles or rooms, and got total gut decontamination with non-absorbable antimicrobials to suppress the potentially pathogenic intestinal microflora; before discharge they were recontaminated with strictly anaerobic faecal flora plus Biogarde R . 26 All blood products for infusion were leucocyte depleted and irradiated with a dose of 25 Gy.
Diagnosis and treatment of GVHD Acute and chronic GVHD were diagnosed and graded according to standard criteria. 27, 28 Acute GVHD was treated with methylprednisolone 2 mg/kg/day intravenously, followed by tapering on improvement; exceptionally another drug, for example, ATG, Campath-monoclonals (anti-CD52) or thalidomide was used.
Criteria for engraftment and response
The day of leucocyte engraftment was defined as the first day at which blood granulocyte counts rose to 0.5 Â 10 9 /l. (for two consecutive determinations) and of platelet engraftment as the first day at which blood platelets rose to 50 Â 10 9 /l (untransfused). Engraftment of different donor cell lineages was documented by XY-FISH analysis in patients with opposite sex donor 29 or by analysis of variable number of tandem repeats 30 and later on of CA repeats 31 with PCR technology.
Statistical analysis
The Kaplan-Meier method was used to estimate the distribution of OS and time to relapse. For the distribution of time to relapse, children were censored when they experienced TRM. Hence, TRM was not modelled as a competing risk, but children with TRM were assumed to have the same potential time-to-relapse distribution as the ones without TRM. Logistic regression analysis was used for evaluation of potential risk factors for development of acute GVHD. Patients who did not survive beyond day þ 50 or received grafts from either cord blood donors or syngeneic donors were excluded from this analysis. Evaluation for chronic GVHD was contingent upon survival to day þ 100. All statistical analyses were performed with the S-PLUS 2000 statistical package.
Po0.05 were considered as statistically significant and referred to the overall best for difference between the curves (log-rank best).
Results
Transplant outcome
Of the 132 patients, 131 engrafted, and one patient died 15 days after SCT, due to an aspergilloma and was not evaluable for engraftment. The median time to engraftment was 27 days for granulocytes and 34 days for thrombocytes. At the end of follow-up, 77 (58%) patients were alive without disease, 47 (36%) had experienced a relapse and 8 patients (6%) had died of transplant-related causes (Table 3 ), of which six within 100 days after transplantation and two between 100 days and 1 year after transplantation.
The 5-year probability of survival was 63, 53 and 74% for children with ALL1, ALL2 and AML1, respectively, whereas the 5-year probability of relapse was 35, 49 and 26% for ALL1, ALL2 and AML1, respectively ( Figure 2 , no significant difference chemotherapy following a relapse (time after relapse: median 4.7, range: 2.9-17.9 years). The effect of acute GVHD on relapse was evaluated for children surviving more than 50 days. Patients who received cells from a syngeneic donor or cord blood were excluded from this evaluation. The incidence of acute GVHD grades II-IV was 6% (seven of 124 evaluable patients). In 14 patients, acute GVHD grade I was suspected on clinical grounds. One patient died due to acute GVHD. Chronic GVHD occurred in 10 patients among 119 evaluable patients (8%); in six it was extensive, but not lethal so far.
Variables possibly related to relapse, OS and acute GVHD after SCT Table 4 summarizes the results on the probability to remain relapse free for 5 years after SCT in our group of patients. Neither the duration of CR1 for the ALL2 patients nor the presence of factors potentially deferring a decreased chance of relapse for AML1 patients were significantly related to occurrence of relapse. Addition of VP-16 in 53 ALL patients and AraC in 25 AML patients did not result in a difference in relapse-free survival. From the other variables evaluated, a younger age of the patient and a lower dose of TBI were significantly related with decreased post-transplantation survival (Figure 3 ). Patient's age and TBI dose were, however, interrelated, since the TBI dose depended on the age of the patient (see Patients and methods and Figure 1 ). Relatively more AML and less ALL cases were found in the (older) children receiving higher TBI dose (2 Â 6 Gy), in accordance with the age distribution at presentation of acute leukaemia, but no differences were present in risk characteristics of the disease (Table 5) . No significant difference in occurrence of relapse was found between children receiving 8 vs 2 Â 6 Gy. Acute GVHD was not significantly related with the occurrence of leukaemia relapse in our patient group as a whole, but, within the AML1 group none of the patients who experienced acute GVHD (n ¼ 9) developed a relapse in contrast to 15 relapse cases in 46 AML1 patients without acute GVHD (likelihood ratio test, including all AML1 patients, P ¼ 0.02).
To evaluate the univariate risk factors for the development of acute GVHD after SCT, we excluded all patients transplanted with cells from syngeneic donors or cells derived from cord blood and patients that did not survive beyond day 50 after SCT. The addition of CsA to the GVHD prophylaxis was not significantly associated with a lower incidence of acute GVHD (P ¼ 0.07), but when GVHD occurred, a clear shift in disease severity was noted; only one out of 13 acute GVHD patients treated with prophylactic MTX/CsA developed grade II or greater vs five out of six acute GVHD patients with MTX alone (P ¼ 0.003). Sex mismatch and CMV status had no influence on the occurrence of acute GVHD in our study group (P ¼ 0.24 and 0.92, respectively). Both higher patient and higher donor age were (as continuous variables) significantly associated with the occurrence of acute GVHD (P ¼ 0.01 and 0.01, respectively; Table 6 ).
Discussion
The aim of the present study was to evaluate the variables associated with transplant-related complications, leukaemia relapse and survival after MSD-haematopoietic SCT for acute leukaemia in a group of children, consecutively grafted in a single centre over a 20-year period. This population is characterized by a low incidence of severe GVHD, due to the gnotobiotic measures, regular microbiological surveillance and preemptive antimicrobial treatment used. 26 This low frequency of severe GVHD and also of TRM provided us the opportunity to study the effect of other variables, such as disease characteristics, age of donor and recipient, pretreatment and non-lethal GVHD on the relapse frequency and survival.
Remarkable progress in (conventional) medical antileukaemia treatment has been made over the past decades. 2, 5, 24 Despite that, the prognosis of infants and children with ALL who have high-risk features (cytogenetic rearrangements, T-cell lineage, poor response to induction therapy and extramedullary disease) 3 is still poor and they may benefit from a SCT in CR1. Although the increasing intensity of chemotherapeutical therapy and advances in supportive care, including nutrition and antibiotics/ antifungals, have improved survival for some of these subtypes of ALL and have made the option of SCT in CR1 sometimes controversial, it seems that the gap between the two treatment strategies increases as the risk profile of the patient worsens. 3, 32 For instance, in patients with the t(9;22) Philadelphia chromosome, the disease-free survival (DFS) was 65% and the OS 72% after SCT in CR1 compared with 25% DFS after chemotherapy alone. 32 In our analysis the OS of children grafted in CR1 of high-risk ALL was 63%, which is comparable to that in other centres. 3, 7, 32 There is evidence to suggest that SCT from HLAidentical donors may provide a superior outcome compared with chemotherapy alone for children in second CR (CR2), after relapse of ALL, especially in patients who have a short CR1 duration. 9, 21, 33 The 5-year OS for all ALL patients transplanted in CR2 was 53%. We observed a trend towards a better outcome for patients who relapsed after a X24 months interval from remission induction, but the difference was not significant, possibly due to small numbers (see Table 4 ).
Owing, in part, to a higher risk of relapse among AML patients in CR1, in contrast to most cases of ALL, there appears to be a role for SCT in first-remission AML children. Many studies demonstrated significantly fewer relapses in patients who received (or were intended to receive) allogeneic SCT. Despite more TRM, the studies all show a superior DFS in the group assigned to allogeneic SCT. 34, 35 For example, in the Children's Cancer Group study, the OS after allogeneic SCT was 60%, which was superior to survival after other strategies that included intensive chemotherapy (53%) and autologous SCT (48%). 4 In the MRC 12 trial, however, the 5-year OS was 66% with intensive chemotherapy only. While SCT decreased the risk of relapse, it did not translate into a significant improvement of OS. 1, 36 Our AML population, referred after remission induction, according to consecutive DCLSG protocols, and selected when they had a MSD, revealed an OS of 74% and a relapse rate of 26% after allogeneic SCT in CR1. These figures represent the outcome of patients, who were treated during a period of more than 20 years. The results suggest that patients with AML who have suitable sibling donors should be offered SCT in CR1. However, the probability of OS of patients with good risk features (based on resistance to therapy and karyotype) treated with chemotherapy alone improved considerably. For these patients, an allogeneic SCT may not improve the outcome. Therefore, many AML study groups nowadays stratify therapy, considering SCT in the intermediate and poor risk groups. [37] [38] [39] Many factors determine the outcome of SCT. Firstly, the GVL effect, mediated by donor alloreactive T cells and associated with the occurrence of acute GVHD, is an important contribution to the control of leukaemia. Its effect is considerably less for cases with acute leukaemia than in CML; 40 AML seems more susceptible to GVL than ALL. 20 In our study, acute GVHD was not significantly associated with the occurrence of leukaemia relapse in the patient group as a whole, but within the AML1 group none of the cases who got acute GVHD developed a relapse, confirming a GVL effect after allogeneic SCT for AML. Withdrawal of CsA in combination with preemptive DLIs 41 or the use of a lower dose of CsA 42 may add to an advantage in leukaemia-free survival of patients with increased risk of relapse, however, at the risk of an increased frequency of severe GVHD.
A second important factor, determining the transplant outcome, is the leukaemia reducing effect of the conditioning regimen. We found that a higher total dose of TBI was associated with a significantly lower risk of relapse and a higher OS. The total dose of TBI in our centre depends on the age of the patient at SCT (see Patients and methods); these variables were confounding in the statistical analysis. For ALL, the influence of age on outcome is very important, as was studied in one clinical trial, in which children and adults were treated with chemotherapy and TBI, according to similar protocols. When corrected for all possible influencing factors, a 20-year-old had a twofold higher risk of treatment failure than a 10-year-old patient. 43 Studies on the influence of age on the outcome of allogeneic SCT for ALL and AML report conflicting data. Some reports find that survival is better in younger patients and some find no influence of age on survival. Up to now, no studies have found an association of the risk of leukaemic relapse post-transplant with age. 44 In contrast, in this study, we report a better DFS in the older children that received a higher dose of TBI (Table 5 ). No significant difference in occurrence of relapse was found between children receiving 8 vs 2 Â 6 Gy, possibly due to low numbers. A higher total dose of TBI may eliminate remaining malignant cells more effectively which could have been monitored with MRD determination post-SCT, not done in this study group. Alternatively, the result of a higher total TBI dose might have been that more cases became complete chimeras, a possible advantage for the control of remnant blast cells after SCT for acute leukaemia. 45 A significant relationship between higher TBI doses and lower relapse incidence and increased OS was recently confirmed by a review of literature comparing various TBI regimens. 46 Conversion of our TBI schedules Gy. Taking into account the calculated BED of different TBI schedules for leukaemic cell kill, the BED of our 2 Â 6 Gy regimen is about 25% higher than the BED of the frequently used 6 Â 2 Gy scheme 46 and 38% higher that the 1 Â 8 Gy scheme. In the young children, however, a possible decreased relapse rate, following higher BED-TBI will need to be weighed against the increased susceptibility for neurodevelopmental and endocrinological adverse effects 18, [47] [48] [49] and secondary cancer. 50 To overcome these side effects, a fractionated TBI dose with higher biologically effective leukaemic cell kill may give superior suppression of malignant disease while limiting adverse effects on other tissues. 46, 51, 52 Data supplied by the acute leukaemia working party (ALWP) of the EBMT confirm the superiority of fractionated TBI for children with ALL in CR2 (n ¼ 525, median dose: 12 Gy, divided into two or more fractions, DFS: 5672%) vs single fraction TBI (n ¼ 245, median dose: 10 Gy, DFS 4473%; P ¼ 0.0008). In the same database, this was not observed for children with AML in CR1. It should be noticed that the ALWP data might contain some bias, as they were not yet adjusted for other possible prognostic factors. Prospective trials comparing TBI schemes with multiple fractions with schemes with a low number of fractions should take the BED for leukaemic cell kill into account. In conclusion, optimization of TBI, total dose and fractionation (especially for ALL), and application of a GVL effect (especially for AML) may further improve the outcome following SCT of children with high-risk acute leukaemia.
